tbuckley/cabot-search huggingface dataset:
Printable Graphene Oxide Micropatterns for a Bio‐Subretinal Chip
Authors: Jia‐Wei Yang, Ming‐Liang Tseng, Yu‐Min Fu, Che‐Hao Kang, Yu‐Ting Cheng, Po‐Han Kuo, Chi‐Kuan Tzeng, Shih‐Hwa Chiou, Chung‐Yu Wu, Guan‐Yu Chen
Journal: Advanced Healthcare Materials (2018)

Abstract Recently, implantable artificial subretinal chips using electronic components have replaced photoreceptors to serve as the most feasible treatment for retinal diseases. As such a chip that is meant to be implanted and used for very long periods, growing retinal cells on it to improve the electrical stimulation efficiency and attraction of neuronal elements remains a challenge. Here, an inkjet printing technology is employed to create graphene oxide (GO) micropatterns onto microelectrodes of a photovoltaic‐powered implantable retinal chip. These GO micropatterns allow human retinal pigment epithelium (RPE) cells to specially attach and grow in each microelectrode. In addition, the cell proliferation, viability, and tight junction of RPE cells are improved during culturing. The development of a simple surface‐coating technology would pave the way for the development of the first fully integrated and encapsulated retinal prostheses with biocompatible on‐chip microelectrodes for long‐term implantation, which could be effectively applied in retina tissue engineering and therapy.
Multiple chemotherapy (CT) lines in metastatic breast cancer (MBC): Which survival benefit for women with hormone receptor (HR)-positive disease?
Authors: Raffaella Palumbo, Antonio Bernardo, Alberto Riccardi, Federico Sottotetti, Cristina Teragni, Giovanni Bernardo
Journal: Journal of Clinical Oncology (2012)

589 Background: Although the development of modern systemic therapies has clearly improved outcome of patients with MBC, the true impact of further CT on overall survival (OS) and QoL of these women is still debated. The aim of this study was to determine which benefit could be brought by successive CT lines in patients with HR-positive disease, aiming to identify factors affecting outcome and survival. Methods: This retrospective analysis included 980 women treated with CT for MBC at our Institution over a eight year period (July 2000-July 2008). With OS data updated in March 2010, the median follow-up was 146 months (range 48-198), OS and time to treatment failure (TTF) were calculated according to the Kaplan-Meyer method for each CT line. Cox proportional hazards model was used to identify factors that could influence TTF and OS. Results: Median OS evaluated from day 1 of each CT line decreased with the line number from 34.8 months for first line to 8.2 months for 7 or more lines). Median TTF ranged from 9.2 months to 7.8 and 6.4 months for the first, second and third line, respectively, with no significant decrease observed beyond the third line (median 5.2 months, range 4.8-6.2). No statistically significant difference was found between HR-positive and HR-negative patients in terms of OS and TTF by each CT line. In univariate analysis factors positively linked to a longer duration of TTF for each CT line were positive hormonal receptor status, more than 3 hormonotherapy lines, absence of liver metastasis, adjuvant CT exposure, response to CT for the metastatic disease; in the multivariate analysis the duration of TTF for each CT line was the only one factor with significant impact on survival benefit for subsequent treatments, in both HR-positive and negative populations (p&lt;0.001). Conclusions: Our results support the benefit of multiple lines of CT in a significant subset of women treated for MBC, since each CT line may contribute to a longer OS. Of interest, such a benefit was also observed for patients with HR-positive disease, although the number of hormonotherpy lines received did not significantly influence the outcome.
Abstract 15777: Elabela, a Novel Apj-receptor Agonist, Improves Fluid Homeostasis and Reduces Cardio-renal Dysfunction During Acute Heart Failure (AHF)
Authors: David Coquerel, Xavier Sainsily, Frederic Chagnon, Alexandre Murza, Lauralyne Dumont, Robert Dumaine, philippe Sarret, Eric Marsault, Dan Salvail, Mannix Auger-Messier, Olivier lesur
Journal: Circulation (2016)

Introduction: Hemodynamics alteration are the hallmark of cardiovascular (CV) and kidney dysfunction/injury induced by AHF. The apelinergic system regulates CV and renal function and is cardioprote...
Abstract 19291: A Multi-Statewide 5-Year Initiative to Improve Care for Out-of-Hospital Cardiac Arrest: Primary Results From the HeartRescue Project
Authors: Sean van Diepen, Saket Girotra, Benjamin Abella, Lance Becker, Bentley Bowbrow, Paul S Chan, Carol Fahrenbruch, Christopher Granger, James G Jollis, Bryan McNally, Linday White, Demitris Yannopoulus, Thomas D Rea
Journal: Circulation (2016)

Background: The HeartRescue Project is a 5 state public health initiative focused on establishing state-wide out-of-hospital cardiac arrest (OHCA) systems of care. Each state worked to engage OHCA ...
Essential Role of Monocyte Chemoattractant Protein-1 in Development of Restenotic Changes (Neointimal Hyperplasia and Constrictive Remodeling) After Balloon Angioplasty in Hypercholesterolemic Rabbits
Authors: EmikoMori, KimihiroKomori, TerutoshiYamaoka, MitsuguTanii, ChuKataoka, AkiraTakeshita, MakotoUsui, KensukeEgashira, KeizoSugimachi
Journal: Circulation (2002)

Background— Renarrowing of dilated arterial sites (restenosis) hampers the clinical benefits of coronary angioplasty. Infiltration and activation of monocytes in the arterial wall mediated by monocyte chemoattractant protein-1 (MCP-1) might be a major cause of restenosis after angioplasty. However, there is no direct evidence to support a definite role of MCP-1 in the development of restenosis. Methods and Results— We recently devised a new strategy for anti–MCP-1 gene therapy by transfecting an N-terminal deletion mutant of the MCP-1 gene into skeletal muscles. We used this strategy to investigate the role of MCP-1 in the development of restenotic changes after balloon injury in the carotid artery in hypercholesterolemic rabbits. Intramuscular transfection of the mutant MCP-1 gene suppressed monocyte infiltration/activation in the injured arterial wall and thus attenuated the development of neointimal hyperplasia and negative remodeling. Conclusions— MCP-1–mediated monocyte infiltration is necessary in t...
Fibroblast Growth Factor-23 Is Not a Single Bystander in Chronic Kidney Disease Mortality
Authors: Solenne Pelletier, Denis Fouque
Journal: Journal of the American Society of Nephrology (2018)

We read with great interest the relationship reported by Marthi et al.1 between fibroblast growth factor-23 (FGF-23), morbidity, and mortality in the general population and patients with CKD. The FGF-23 increase has been described in patients with CKD who are unable to clear phosphate from blood, leading to a rapid increase in FGF-23 production and serum concentration. However, FGF-23 does not stand alone in this early metabolic disorder,2 and Klotho, its cofactor, is also a major compound to consider.3 We recently reported two important observations4 on FGF-23/Klotho related to the findings of Marthi et al.1 In a 2-year prospective cohort of 235 patients on maintenance hemodialysis, we found that a serum FGF-23 increase by 10 RU/ml was associated with a 7% greater cardiovascular morbidity and mortality, whereas a serum Klotho above 280 ng/L was associated with a 14% lower event rate. Importantly, these significant associations were independent from each other. Thus, the protection brought by Klotho seems greater than the deleterious FGF-23 effect on cardiovascular events.4 Furthermore, patients with a high Klotho did not present increased morbidity and mortality associated with a high FGF-23. This key information may decipher the pathogenic role of FGF-23 in specific organs.5 FGF-23 may exert its cardiac toxicity only if serum Klotho is reduced, such as has been convincingly shown in an animal model by Hu et al.6 and advocated in our clinical study.4 Thus, the well established association between FGF-23 and mortality is confirmed here by Marthi et al.1 However, analyzing the FGF-23 effect without Klotho data may overemphasize the deleterious effect of FGF-23. It should be interesting to measure Klotho in long-term studies addressing cardiovascular events and FGF23 determination. This may confirm an independent pathogenic FGF23 effect as proposed by Grabner et al.5 or support the absence of causality between high FGF23 and survival suggested by Marthi et al.1 Disclosures None.
How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria
Authors: Marta Mosca, Karen H. Costenbader, Sindhu R. Johnson, Valentina Lorenzoni, Gian Domenico Sebastiani, Bimba F. Hoyer, Sandra Navarra, Eloisa Bonfa, Rosalind Ramsey‐Goldman, Jorge Medina‐Rosas, Matteo Piga, Chiara Tani, Sara K. Tedeschi, Thomas Dörner, Martin Aringer, Zahi Touma
Journal: Arthritis & Rheumatology (2018)

Systemic lupus erythematosus (SLE) presents with nonspecific signs and symptoms that are also found in other conditions. This study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.Academic lupus centers in Asia, Europe, North America, and South America collected baseline data on patients who were referred to them during the previous 3 years for possible SLE and who had a symptom duration of <1 year. Clinical and serologic manifestations were compared between patients diagnosed as having SLE and those diagnosed as having SLE-mimicking conditions. Diagnostic performance of the 1997 American College of Rheumatology (ACR) SLE classification criteria and the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE classification criteria was tested.Data were collected on 389 patients with early SLE and 227 patients with SLE-mimicking conditions. Unexplained fever was more common in early SLE than in SLE-mimicking conditions (34.5% versus 13.7%, respectively; P < 0.001). Features less common in early SLE included Raynaud's phenomenon (22.1% versus 48.5%; P < 0.001), sicca symptoms (4.4% versus 34.4%; P < 0.001), dysphagia (0.3% versus 6.2%; P < 0.001), and fatigue (28.3% versus 37.0%; P = 0.024). Anti-double-stranded DNA, anti-β2 -glycoprotein I antibodies, positive Coombs' test results, autoimmune hemolytic anemia, hypocomplementemia, and leukopenia were more common in early SLE than in SLE-mimicking conditions. Symptoms detailed in the ACR and SLICC classification criteria were significantly more frequent among those with early SLE. Fewer patients with early SLE were not identified as having early SLE with use of the SLICC criteria compared to the ACR criteria (16.5% versus 33.9%), but the ACR criteria demonstrated higher specificity than the SLICC criteria (91.6% versus 82.4%).In this multicenter cohort, clinical manifestations that could help to distinguish early SLE from SLE-mimicking conditions were identified. These findings may aid in earlier SLE diagnosis and provide information for ongoing initiatives to revise SLE classification criteria.
Antidepressant induced weight gain associated with anti-histaminergic activity
Authors: Virginio Salvi, Claudio Mencacci, Francesco Barone-Adesi
Journal: BMJ (2018)

Serretti and Porcelli rightly put the matter of antidepressant induced weight gain in the spotlight.1

Given the widespread use of antidepressants, we must assess which ones are associated with weight gain. In a reanalysis of data from the large meta-analysis of Serretti and Mandelli,2 we found that the …
Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy
Authors: KarenSliwa, LoriBlauwet, KemiTibazarwa, ElenaLibhaber, Jan-PeterSmedema, AnthonyBecker, JohnMcMurray, HaticeYamac, SaidaLabidi, IngridStruman, DeniseHilfiker-Kleiner
Journal: Circulation (2010)

Background— Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart disease that occurs in previously healthy women. We identified prolactin, mainly its 16-kDa angiostatic and proapoptotic form, as a key factor in PPCM pathophysiology. Previous reports suggest that bromocriptine may have beneficial effects in women with acute onset of PPCM. Methods and Results— A prospective, single-center, randomized, open-label, proof-of-concept pilot study of women with newly diagnosed PPCM receiving standard care (PPCM-Std; n=10) versus standard care plus bromocriptine for 8 weeks (PPCM-Br, n=10) was conducted. Because mothers receiving bromocriptine could not breast-feed, the 6-month outcome of their children (n=21) was studied as a secondary end point. Blinded clinical, hemodynamic, and echocardiographic assessments were performed at baseline and 6 months after diagnosis. Cardiac magnetic resonance imaging was performed 4 to 6 weeks after diagnosis in PPCM-Br patients. There were no significant diff...
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
Authors: Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, Anjali S. Advani, Daniel J. DeAngelo, Tibor J. Kovacsovics, Anand Jillella, Dale Bixby, Moshe Y. Levy, Megan M. O’Meara, Phoenix A. Ho, Jenna Voellinger, Anthony S. Stein
Journal: Blood (2018)
Reply to Riccardo Bertolo's Letter to the Editor re: Giorgio Gandaglia, Carlo Andrea Bravi, Paolo Dell’Oglio, et al. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. Eur Urol 2018;74:4–7
Authors: Giorgio Gandaglia, Nicola Fossati, Francesco Montorsi, Alberto Briganti
Journal: European Urology (2018)
A Phase 3 Trial of <scp>l</scp> -Glutamine in Sickle Cell Disease
Authors: Yutaka Niihara, Scott T. Miller, Julie Kanter, Sophie Lanzkron, Wally R. Smith, Lewis L. Hsu, Victor R. Gordeuk, Kusum Viswanathan, Sharada Sarnaik, Ifeyinwa Osunkwo, Edouard Guillaume, Swayam Sadanandan, Lance Sieger, Joseph L. Lasky, Eduard H. Panosyan, Osbourne A. Blake, Tamara N. New, Rita Bellevue, Lan T. Tran, Rafael L. Razon, Charles W. Stark, Lynne D. Neumayr, Elliott P. Vichinsky
Journal: New England Journal of Medicine (2018)

Oxidative stress contributes to the complex pathophysiology of sickle cell disease. Oral therapy with pharmaceutical-grade l-glutamine (USAN, glutamine) has been shown to increase the proportion of the reduced form of nicotinamide adenine dinucleotides in sickle cell erythrocytes, which probably reduces oxidative stress and could result in fewer episodes of sickle cell–related pain.
SP0026 Biosimilars – the changing views of pare’s member organisations
Authors: D. Wiek
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> After EULAR PARE's position paper "Biosimilars – what do patients need to consider" published in November 2015 more biosimilars for rheumatic diseases have been approved by EMA (European Medicine Agency), have entered the market in different European countries and more biosimilars will be marketed. New studies and data informing about the use of biosimilars, as well as feedback received from patient organisations and in particular from PARE organisations, have made it necessary to update PARE's 2015 position. Biological therapies are enormous cost factors for the healthcare system and biological therapies have to be affordable, what is seen as difficult in various countries. But an optimal quality healthcare is enormously important for the individual patient (e.g. fewer sick days, less hospitalisation, less disabilities), prevents early retirement and thus saves costs and contributes to a country's economic and social system. If so-called naïve patients should take a biologic, the less expensive biosimilar can be used, as long as there are no contraindications, the patient has been informed and the decision is based on a shared decision between rheumatologist and patient. But transitioning users from an originator to a biosimilar is very controversial and seen critically by PARE's patient organisations. The talk will cover the changing views concerning extrapolation, one-time switch, multiple therapy switches, registries and the relevance of the application form for patients. <h3>Disclosure of Interest</h3> None declared
Brexit: money released from EU membership will help fund long term NHS, says May
Authors: Susan Mayor
Journal: BMJ (2018)

The government has said that the UK “will allow free movement for skilled workers” after Brexit, although it has given few details about how this will relate to NHS staff.

In an introduction to the white paper on the UK’s future relations with the European Union the prime minister, Theresa May, said that future legislation would “ensure that we leave the EU, without leaving Europe.”1 She said that it would “enable cooperation to continue in areas including science and international development, improving people’s lives within and beyond Europe’s borders.”

May suggested that leaving the EU would release money previously given in annual contributions to the EU budget “for domestic priorities—in particular our long term plan for the NHS.”

The white paper,1 published on 12 July, …
収縮は維持されている奇異な低血流,低勾配の重症大動脈弁狭窄症 有病率及び臨床特性
Authors: Maeda Mika, Ohara Takahiro, Nakatani Satoshi, Kanzaki Hideaki, Kim Jiyoong, Hashimura Kazuhiko, Kitakaze Masafumi
Journal: Circulation (2008)
Clinical trial transparency in the Americas: the need to coordinate regulatory spheres
Authors: Trudo Lemmens, Carlos Herrera Vacaflor
Journal: BMJ (2018)

Numerous initiatives have contributed to health data transparency in the Americas, but further coordinated effort is needed to ensure the reliability of research for health, argue <b>Trudo Lemmens</b> and <b>Carlos Herrera Vacaflor</b>
Profiling uptake of single site testing (SST) for familial cancer (CA) risk in an administrative genetic testing database.
Authors: Michael J. Hall, Katen C. McCully, Karthik Devarajan, Rajesh R. Kaldate, Mary Beryl Daly
Journal: Journal of Clinical Oncology (2012)

1550 Background: Among the anticipated social and cost-saving benefits to identifying a mutation in a CA predisposition gene in an individual is the subsequent opportunity to perform SST in close relatives to confirm risk status and to guide risk-reducing interventions. Despite ample research into uptake of primary genetic testing for Lynch syndrome (LS) and hereditary breast ovarian syndrome (HBOS) among moderate- and high-risk individuals, few studies have focused on the resultant cascade of SST that is predicted to follow in families. Methods: Administrative data on 2,631 consecutive single-site mutation tests performed over a 3-month interval (12/1/10-2/28/11) were obtained from a commercial genetic testing database maintained by Myriad Genetic Laboratories. 14 subjects (29 tests) were excluded due to multiple entries. Demographic, personal/family history (hx), and provider data are collected on a Test Requisition Form included in kits. All statistical tests are 2-sided (α=0.05). Results: Women had SST more often than men (HBOS 82.8%; LS 65.5%). Mean age at time of SST was 42.7 yrs, and was higher for HBOS than LS (p=0.01). Among subjects with hx of CA, mean age at CA diagnosis (dx) was similar (HBOS 48.6; LS 48.7 yrs). Subjects reported CA in &gt;1 relatives (range 1-16) with a mean age at dx 40.1 yrs. Compared to HBOS, those tested for LS were more likely to report CA in a 1st degree relative (81.3 vs 74.4%, p=0.001) and a lower age of youngest CA dx in the family (p&lt;0.001). Non-European ancestry was more common for HBOS SST than LS (30.0 vs 24.8%) (p=0.05). SST positive test rate was no different by syndrome or ancestry, but was higher for men (47.5 vs 42.0%, p=0.02). Conclusions: Uptake of commercial SST in high-risk families is uneven by age, sex, ancestry and CA syndrome. While between-syndrome variability in CA risks may explain some differences, more research is needed to understand barriers to uptake of SST among at-risk individuals if CA prevention goals are to be realized. [Table: see text]
원저 : 한국인 만성 B 형 간염 바이러스 감염에서 Precore 및 Core promoter 변이의 발현빈도 및 임상적 의의
Authors: 김형준(Hyung Joon Kim), 유병철(Byung Chul Yoo)
Journal: Clinical and Molecular Hepatology (2002)

목적 : 한국에서 B형 간염바이러스의 precore 및 core promoter 변이의 발현에 관한 보고들이 있었으나 그 빈도나 임상적 의의는 정확히 밝혀지지 않았다. 본 연구에서는 한국인 만성 B형 간염 바이러스 감염에서 precore 및 core promoter 변이의 발현 빈도를 알아보고 이들 변이와 HBeAg 상태, 바이러스 증식도 및 간질환과의 상관관계를 밝히고자 하였다. 대상과 방법 : 1998년 12월부터 1999년 8월까지 중앙대학교 병원 간질환 클리닉을 방문한 환자 중 혈청 HBeAg 양성이고 HBV-DNA가 bDNA assay상 양성인 50명, 혈청 HBeAg 음성이고 bDNA 양성인 50명, 혈청 HBeAg 음성이고 bDNA 음성인 50명의 환자들을 무작위로 추출하여 이들 환자들에서 혈청 HBV-DNA를 PCR로 증폭하였고 PCR방법으로 HBV-DNA가 양성인 135명에서 HBV-DNA의 precore 및 core promoter 부위의 염기서열을 분석하였다. 결과 : 염기서열 분석이 가능하였던 135예 모두에서 T1858을 갖는 유전자형이 검출되었다. Precore 변이 (A1896)는 HBeAg 음성 bDNA 양성인 환자의 95.7%, HBeAg 음성 bDNA 음성인 환자의 94.9%에서 검출되었다. HBeAg 양성 bDNA 양성인 환자들 중에서는 88%에서 야생형 바이러스, 12%에서는 야생형과 A1896 변이종의 혼합 감염이 관찰되었다. Core promoter TA 변이는 HBeAg 양성 환자의 74%, HBeAg 음성 bDNA 양성인 환자의 93.5%, HBeAg 음성 bDNA 음성인 환자의 94.9%에서 검출되었다. Precore 변이 및 core promoter TA변이의 유무는 간경변증의 유무나 ALT 치의 상승 유무와 상관관계가 없었으며 HBV-DNA 치와도 상관관계가 없었다. HBeAg 음성 환자들 중 bDNA 측정법으로 혈청 HBV-DNA가 검출된 50명중 46명 (92%)에서 임상적 혹은 생 화학적인 간질환의 증거가 관찰된 반면 HBeAg 음성 bDNA 음성인 환자들 중 40%에서 임상적 혹은 생화학적인 간질환의 증거가 관찰되었다. 결론 : HBV C 유전자형에 감염된 한국인에서 precore 변이는 HBeAg 음전 시기에 거의 항상 일어나며 바이러스의 증식정도 혹은 간질환의 중증도와 관련이 없었다. Core promotor TA 변이는 바이러스의 증식정도 혹은 간질환의 중증도와 상관없이 HBeAg 양성 및 음성 환자들에서 흔하게 관찰되었다. HBeAg 음성인 환자들 중에서도 높은 바이러스 혈증을 보이는 환자들이 있으며 이들은 낮은 바이러스 혈증을 보이는 환자들에 비하여 보다 심하고 진행된 간질환을 갖고 있었다.
Annals Story Slam - Only at Temple
Authors: Sue Gersh
Journal: Annals of Internal Medicine (2018)

Web Exclusives17 July 2018Annals Story Slam - Only at TempleFREESue Gersh, MDSue Gersh, MDBassett Healthcare, Cooperstown, New York (S.G.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W18-0019 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Only at Temple "Only at Temple," by Sue Gersh (Duration 6:02)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Bassett Healthcare, Cooperstown, New York (S.G.)Corresponding Author: Sue Gersh, MD; e-mail, susan.[email protected]temple.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 July 2018Volume 169, Issue 2Page: SS1 ePublished: 17 July 2018 Issue Published: 17 July 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.Loading ...